AbCellera Biologics Inc. · Q2 2026
ReportedAug 5, 2026
Period endedJun 30, 2026
Rule of 40n/m
The quarter in short
Revenue $4M, down 76.3% year over year and 51.3% on the quarter. EPS −$0.18, down 50.0% year over year and 28.6% on the quarter. Free cash flow $24M.
Reported this quarter
Revenue
$4M
QoQ −51.3%
YoY −76.3%
EPS
−$0.18
QoQ −28.6%
YoY −50.0%
Free Cash Flow
$24M
QoQ —
YoY —
FCF Margin
587.4%
QoQ +1036.7 pp
YoY +855.3 pp
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
On the call: Q2 2026 call.
Coverage around this release
R40
AbCellera Spent $1 Billion Building an Antibody Factory. ABCL635 Is Its First Real Test.
In-Depth · Aug 26, 2026
R40
AbCellera Joins Coverage and Five of Its Last Eight Quarters Cannot Be Scored.
News · Aug 25, 2026
News
AbCellera prices $200 million offering at $9.75
SEC 424B5
News
ABCL635 meets both Phase 2 primary endpoints
SEC 8-K Ex-99.1
News
Q2 2026: revenue $4.1M, net loss $55.4M
SEC 8-K Ex-99.1
News
Vertex T-cell engager collaboration
SEC 8-K Ex-99.1
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1703057.
HTML
8-K results announcement
Filed Aug 5, 2026
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
149 KB
HTM
Exhibit EX-99.2
Exhibit 99.2 to the 8-K
11 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Jun 30, 2026, filed Aug 5, 2026
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure ABCL has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q2 2026, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings